Core Viewpoint - Lepu Medical (300003.SZ) has reversed its declining performance, projecting significant growth in its 2025 annual results, with expected net profit ranging from 800 million to 1.2 billion yuan, representing a year-on-year increase of 223.97% to 385.95% [1][2] Financial Performance - For 2025, Lepu Medical anticipates both net profit and non-net profit to be between 800 million and 1.2 billion yuan, with median estimates indicating a growth of approximately 304.86% and 352.49% compared to the previous year [2] - The company experienced a decline in revenue and net profit in 2023 and 2024, with net profit dropping by 42.91% and 80.37% respectively [3][4] Business Segments - The core business of cardiovascular interventional devices has shown stable revenue growth, while the pharmaceutical segment has achieved double-digit growth due to the completion of inventory clearance in retail channels [5] - Strategic emerging sectors, including innovative drugs and dermatology, have contributed to the performance increase [5] Research and Development - Lepu Medical has consistently invested over 1 billion yuan annually in R&D, with total R&D expenditures from 2021 to 2024 being 11.12 billion, 12.84 billion, 12.42 billion, and 11.65 billion yuan respectively [7] - The company has developed several "firsts" in domestic medical technology, including bioabsorbable stents and dual-chamber cardiac pacemakers, establishing a strong competitive edge in the cardiovascular field [7] Financial Health - As of September 2025, the company's debt-to-asset ratio is approximately 30.71%, indicating a solid financial position [8] - Lepu Medical's operating cash flow has consistently shown net inflows, with a projected year-on-year increase of about 95% for 2025 [8]